Introduction
Growth hormone (GH) secretagogue research has advanced considerably with the development of synthetic peptides that stimulate endogenous GH release through distinct hypothalamic-pituitary pathways. Two of the most widely studied compounds in this category are CJC-1295 (No DAC), a growth hormone-releasing hormone (GHRH) analog, and ipamorelin, a selective growth hormone-releasing peptide (GHRP).
These peptides operate through complementary mechanisms and are frequently co-administered in research protocols to investigate synergistic GH release patterns. Understanding their individual pharmacology and combined effects is essential for researchers designing studies around the somatotropic axis.
This article provides a detailed comparison of CJC-1295 and ipamorelin for research purposes. Both compounds are available as research-grade lyophilized peptides from Proxiva Labs: CJC-1295 No DAC and Ipamorelin, each with verified third-party purity testing.
CJC-1295 (No DAC) Overview
Mechanism of Action
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH, also known as somatoliberin), the 44-amino acid hypothalamic peptide that stimulates GH secretion from anterior pituitary somatotrophs. CJC-1295 consists of the first 29 amino acids of GHRH (known as modified GRF 1-29 or Mod GRF 1-29) with four amino acid substitutions at positions 2, 8, 15, and 27 that dramatically improve metabolic stability and resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV).
The “No DAC” designation indicates the absence of the Drug Affinity Complex, a lysine-maleimidopropionic acid linker used in some formulations to extend half-life through albumin binding. The No DAC version produces more physiological, pulsatile GH release patterns, which many researchers prefer for studies investigating natural GH secretory dynamics (Teichman et al., 2006).
Key Research Findings
Studies indicate that CJC-1295 (No DAC) administration results in:
- Amplified GH pulses: Increases the amplitude of natural GH secretory episodes without altering pulse frequency
- IGF-1 elevation: Sustained increases in insulin-like growth factor-1 levels over multi-day protocols
- Preserved feedback mechanisms: Maintains somatostatin-mediated negative feedback, preventing supraphysiological GH spikes
- Improved body composition markers: In preclinical models, associated with favorable changes in lean mass and fat mass ratios
Ipamorelin Overview
Mechanism of Action
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist of the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor. Unlike earlier GHRPs such as GHRP-6 and GHRP-2, ipamorelin is notable for its high selectivity—it stimulates GH release without significantly affecting cortisol, prolactin, or adrenocorticotropic hormone (ACTH) levels at standard research concentrations.
This selectivity profile makes ipamorelin particularly valuable for research protocols where investigators need to isolate GH-specific effects without confounding hormonal variables. Ipamorelin stimulates GH release from the pituitary by mimicking the action of ghrelin at the GHS-R1a receptor, which is mechanistically distinct from and complementary to the GHRH receptor pathway (Raun et al., 1998).
Key Research Findings
Research in preclinical models has demonstrated several notable characteristics of ipamorelin:
- Selective GH release: Dose-dependent GH secretion without elevating cortisol or prolactin at physiological concentrations
- Bone density effects: Studies in ovariectomized rat models showed increased bone mineral content and improved bone microarchitecture
- GI motility: Investigation as a prokinetic agent for post-operative ileus, with promising results in accelerating gastric emptying
- Consistent GH response: Unlike some GHRPs, ipamorelin appears to maintain its GH-releasing efficacy over extended research protocols without significant tachyphylaxis
Key Differences: Head-to-Head Comparison
| Parameter | CJC-1295 (No DAC) | Ipamorelin |
|---|---|---|
| Drug Class | GHRH analog (Mod GRF 1-29) | GHRP / ghrelin mimetic |
| Receptor Target | GHRH receptor (pituitary somatotrophs) | GHS-R1a (ghrelin receptor) |
| Peptide Length | 29 amino acids (modified) | 5 amino acids |
| GH Release Pattern | Amplifies pulse amplitude; requires existing GH pulse | Initiates GH pulse independently |
| Cortisol Effects | Minimal | Minimal (highly selective) |
| Prolactin Effects | None reported | None at standard research doses |
| Hunger Stimulation | Not typically reported | Minimal (unlike GHRP-6) |
| Half-Life | ~30 minutes (No DAC version) | ~2 hours |
| Primary Research Use | GH pulse amplification, IGF-1 studies | Selective GH stimulation, bone, GI motility |
Research Applications
The Stacking Rationale
The combination of CJC-1295 (No DAC) and ipamorelin is one of the most studied peptide stacks in GH research. The scientific rationale is straightforward: these peptides act through two distinct receptor pathways that converge on the same endpoint—growth hormone release from pituitary somatotrophs.
CJC-1295 stimulates the GHRH receptor, which amplifies GH pulse amplitude. Ipamorelin stimulates the ghrelin receptor, which initiates GH pulses. When co-administered, research suggests the combination produces a synergistic effect—the total GH output exceeds the sum of each peptide administered alone. This is sometimes described as the “push-pull” mechanism: GHRH pushes GH release while GHRPs pull it.
Additionally, simultaneous GHRH and GHRP administration has been shown in studies to partially overcome somatostatin tone, the inhibitory signal that normally suppresses GH between pulses. This means the combined approach may produce more robust GH elevations than either peptide alone.
Aging and Body Composition Research
The somatopause—the age-related decline in GH and IGF-1 secretion—is a significant area of research interest. Both CJC-1295 and ipamorelin are studied as tools for investigating whether restoring youthful GH pulse patterns can influence age-related changes in body composition, bone density, and metabolic function.
Related Compounds
Researchers working in the GH secretagogue space may also be interested in tesamorelin, a GHRH analog that has been studied for its effects on visceral adiposity and hepatic fat content. Our research hub provides additional guides on growth hormone peptides and their applications.
Reconstitution and Research Handling
Both CJC-1295 (No DAC) and ipamorelin are supplied as lyophilized powders. Standard reconstitution uses bacteriostatic water with gentle swirling (never vortexing) to preserve peptide structure. Reconstituted solutions should be stored at 2-8°C and used within the timeframe specified by the research protocol. Both peptides are relatively stable but should be protected from light and repeated temperature fluctuations.
Browse our complete selection of research peptides for your laboratory needs.
Conclusion
CJC-1295 (No DAC) and ipamorelin represent two complementary approaches to growth hormone research. CJC-1295 amplifies natural GH pulses through the GHRH receptor, while ipamorelin initiates GH release through the ghrelin receptor with exceptional hormonal selectivity. Together, they form arguably the most well-characterized peptide combination in GH secretagogue research, offering investigators a powerful tool for studying the somatotropic axis without the confounding hormonal effects seen with earlier-generation GHRPs.
Explore research-grade CJC-1295 No DAC and Ipamorelin at Proxiva Labs—currently 30% off with free shipping on qualifying orders. All compounds verified by independent testing.
References
- Teichman, S. L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. doi:10.1210/jc.2005-1536
- Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. doi:10.1530/eje.0.1390552
- Bowers, C. Y. (2012). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 55(8-9), 1066-1078. PMID: 9900427
This article is for informational purposes only. All compounds mentioned are strictly for research use. Consult applicable regulations before purchasing research compounds.